Drugs that contain Selpercatinib
1. List of Retevmo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10584124 | LOXO ONCOLOGY INC | Crystalline forms |
Oct, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10137124 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10172851 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10786489 | LOXO ONCOLOGY INC | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 8, 2025 |
| Orphan Drug Exclusivity (ODE) | May 8, 2027 |
NCE-1 date: 2024-05-08
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; The treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory
Dosage: CAPSULE;ORAL
RETEVMO family patents
26
United States
7
Japan
4
China
4
Korea, Republic of
4
Israel
4
European Union
3
Brazil
3
Argentina
3
Taiwan, Province of China
3
EA
3
Canada
3
Australia
2
Uruguay
2
Mexico
2
Morocco
1
Portugal
1
Moldova, Republic of
1
Singapore
1
Spain
1
Jordan
1
Croatia
1
Costa Rica
1
Colombia
1
Dominican Republic
1
Philippines
1
Peru
1
Tunisia
1
Lithuania
1
Hungary
1
Saudi Arabia
1
Slovenia
1
Ukraine
1
Poland
1
Chile
1
RS
1
Ecuador
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic